

HB 977

2026

A bill to be entitled  
An act relating to benefits for obesity under the state group health insurance plan; amending s. 110.12303, F.S.; requiring the Department of Management Services to provide coverage for the treatment and management of obesity for state group health insurance policies issued after a specified date; providing coverage criteria; requiring the department to adopt eligibility criteria by a specified date; providing definitions; providing reporting requirements; providing an effective date.

Be It Enacted by the Legislature of the State of Florida:

Section 1. Subsection (9) is added to section 110.12303, Florida Statutes, to read:

110.12303 State group insurance program; additional benefits; price transparency program; reporting.—

(9) (a) For state group health insurance plan policies issued on or after January 1, 2027, the department shall provide coverage for evidence-based treatment and management of obesity and related conditions, as prescribed by a professional health care provider, for:

1. Intensive health behavioral and lifestyle treatment.
2. United States Food and Drug Administration-approved

26 weight management medications.

27 (b) Coverage criteria for a United States Food and Drug  
28 Administration-approved weight management medication may not be  
29 more restrictive than the United States Food and Drug  
30 Administration indications for such medication. Coverage for  
31 intensive health behavioral and lifestyle treatment may include  
32 interventions certified by or recognized by the United States  
33 Centers for Disease Control and Prevention or recommended by  
34 current clinical standards of care. Services may be provided in  
35 person, virtually, or in community-based settings to support  
36 patient access and needs.

37 (c) Before January 1, 2027, the department shall adopt  
38 eligibility criteria, which shall require patients to:

39 1. Be enrolled in a PPO or HMO plans.  
40 2. Be 18 years of age or older.  
41 3. Be referred and supervised by an in-network licensed  
42 provider.

43 4. Consent to provide personal and medical information to  
44 the department, including medical records documenting body mass  
45 index and weight related comorbidities.

46 5. Have received a clinical diagnosis of obesity by an in-  
47 network licensed provider.

48 6. Participate in intensive health, behavioral, and  
49 lifestyle intervention.

50 (d) As used in this subsection, the term:

51       1. "United States Food and Drug Administration-approved  
52 weight management medication" means any Glucagon-like peptide-1  
53 agonist medication approved by the United States Food and Drug  
54 Administration with an indication for chronic weight management  
55 in patients with an obesity diagnosis.

56       2. "Intensive health behavioral and lifestyle treatment"  
57 means an evidence-based, intensive, multicomponent behavioral or  
58 lifestyle modification intervention that supports healthy weight  
59 management and is delivered in person or through telehealth as  
60 defined in s. 456.47(1).

61       (e) On or before January 15, 2028, and annually  
62 thereafter, the department shall report to the Governor, the  
63 President of the Senate, and the Speaker of the House of  
64 Representatives on the participation level and cost savings to  
65 both the enrollee and the state resulting from this subsection.

66       **Section 2.** This act shall take effect July 1, 2026.